HLX13

DRUG3 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Healthy Male VolunteersHepatocellular Carcinoma (HCC)

Phase 1

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Shanghai Henlius BiotechHealthy Male Volunteers

Start: 2023-11-28End: 2024-05-28Target: 304Updated: 2023-12-06

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

RecruitingNCT07176650

Shanghai Henlius BiotechHepatocellular Carcinoma (HCC)

Start: 2025-11-25End: 2026-12-01Target: 246Updated: 2026-03-16

Phase 3

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Not yet recruitingNCT06841185

Shanghai Henlius BiotechHepatocellular Carcinoma (HCC)

Start: 2025-04-30End: 2028-05-05Target: 656Updated: 2025-02-24